MARKSANS

Marksans Pharma Share Price

₹249.00 -10.15 (-3.92%)

22 Jan, 2025 12:16

SIP TrendupStart SIP in MARKSANS

Start SIP

Performance

  • Low
  • ₹248
  • High
  • ₹260
  • 52 Week Low
  • ₹130
  • 52 Week High
  • ₹359
  • Open Price₹260
  • Previous Close₹259
  • Volume467,239

Investment Returns

  • Over 1 Month -18.33%
  • Over 3 Month -9.14%
  • Over 6 Month + 34.33%
  • Over 1 Year + 59.11%
SIP Lightning

Smart Investing Starts Here Start SIP with Marksans Pharma for Steady Growth!

Invest Now

Marksans Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 32.5
  • PEG Ratio
  • 2
  • Market Cap Cr
  • 11,284
  • P/B Ratio
  • 4.9
  • Average True Range
  • 12.22
  • EPS
  • 7.66
  • Dividend Yield
  • 0.2
  • MACD Signal
  • -12.04
  • RSI
  • 35.6
  • MFI
  • 29.55

Marksans Pharma Financials

Marksans Pharma Technicals

EMA & SMA

Current Price
₹249.00
-10.15 (-3.92%)
pointer
  • stock-down_img
  • Bearish Moving Average 14
  • stock-up_img
  • Bullish Moving Average 2
  • 20 Day
  • ₹277.30
  • 50 Day
  • ₹289.44
  • 100 Day
  • ₹279.09
  • 200 Day
  • ₹246.11

Resistance and Support

263.87 Pivot Speed
  • R3 286.18
  • R2 280.32
  • R1 269.73
  • S1 253.28
  • S2 247.42
  • S3 236.83

What's your outlook on Marksans Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Marksans Pharma Ltd. is a global pharmaceutical company engaged in the research, development, and manufacturing of generic drugs. It offers a wide range of pharmaceutical formulations, serving key therapeutic areas such as pain management, cardiovascular, and gastrointestinal.

Marksans Pharma has an operating revenue of Rs. 2,378.68 Cr. on a trailing 12-month basis. An annual revenue growth of 17% is outstanding, Pre-tax margin of 19% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 12% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -19% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 82 which is a GOOD score indicating consistency in earnings, a RS Rating of 80 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 60 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Marksans Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results
2024-08-13 Quarterly Results
2024-05-30 Audited Results & Final Dividend
2024-02-13 Quarterly Results
2023-11-09 Quarterly Results
Date Purpose Remarks
2024-09-17 FINAL Rs.0.60 per share(60%)Final Dividend
2023-06-07 FINAL Rs.0.50 per share(50%)Final Dividend
View More

Marksans Pharma F&O

Marksans Pharma Shareholding Pattern

43.87%
3.15%
11.07%
0%
26.24%
15.67%

About Marksans Pharma

  • NSE Symbol
  • MARKSANS
  • BSE Symbol
  • 524404
  • Chairman & Managing Director
  • Mr. Mark Saldanha
  • ISIN
  • INE750C01026

Similar Stocks to Marksans Pharma

Marksans Pharma FAQs

Marksans Pharma share price is ₹249 As on 22 January, 2025 | 12:02

The Market Cap of Marksans Pharma is ₹11283.8 Cr As on 22 January, 2025 | 12:02

The P/E ratio of Marksans Pharma is 32.5 As on 22 January, 2025 | 12:02

The PB ratio of Marksans Pharma is 4.9 As on 22 January, 2025 | 12:02

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23